Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells

Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study, we aim to use RIC followed by matched related/unrelated donor, 7/8 matched related/unrelated donor, or haploidentical donor peripheral blood stem cell transplantation. Standard strategies to control the alloreactivity following HCT utilize immunosuppressive or cytotoxic medications. In this study, we explore donor graft engineering to enrich for immmunoregulatory populations to facilitate post transplantation immune reconstitution while minimizing graft versus host disease (GVHD) with post-transplant immunosuppressive agents.

Study Overview

• Status: Recruiting
• Conditions: Myelodysplastic Syndromes; Myeloproliferative Disorders; Acute Leukemia; Chronic Myelogenous Leukemia; Allogeneic Hematopoietic Cell Transplantation (HCT); Advanced Hematologic Malignancies
• Intervention / Treatment: Drug: Fludarabine; Device: CliniMACS CD34 Reagent System; Drug: Tacrolimus; Drug: Cyclophosphamide; Drug: Plerixafor; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Drug: Melphalan; Drug: Thiotepa; Drug: Mycophenolate Mofetil (MMF); Drug: Ruxolitinib

Detailed Description

The objectives for the study are listed below:

Primary Objectives

*Determine the safety, and feasibility of administration of several dose combinations of conventional T-cells (Tcon) and regulatory T-cells (Treg) in subjects undergoing allogeneic hematopoietic cell transplantation (HCT) with related/unrelated HLA-matched or mismatched donors, or haploidentical donors with reduced intensity conditioning preparative regimen.

Secondary Objectives

• To determine the GVHD-free relapse-free survival (GRFS) post-HCT
• To determine the overall survival (OS) post-HCT
• To measure the incidence and severity of acute and chronic GVHD

Exploratory Objectives

• To measure the incidence of serious infections
• To measure the incidence and timing of engraftment
• To measure T cell immunity reconstitution parameters

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Lindsay Danley; Phone Number: 650-736-0304; Email: lindsmd@stanford.edu

Study Locations

• United States
  • California
    • Stanford, California, United States, 94304
      • Recruiting
      • Stanford University
      • Principal Investigator: Everett Meyer, MD, PhD
      • Contact: Lindsay Danley; Phone Number: 650-736-0304; Email: lindsmd@stanford.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Recipient Inclusion Criteria

a. Patients with the following diseases that are histopathologically-confirmed are eligible

• Acute myeloid, lymphoid, or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) or beyond first complete remission (CR1) without the presence of minimal residual disease
• Acute myeloid, leukemia, or mixed phenotype leukemia that is either:
• Not in morphologic CR with bone marrow infiltration by leukemic blasts of ≤10%, or
• In morphologic CR with evidence of minimal residual disease positivity by either multiparametric flow cytometric analysis or by a nucleic acid-based technique
• Primary refractory acute myeloid, lymphoid, or mixed phenotype leukemia
• Chronic myelogenous leukemia (accelerated, blast or second chronic phase)
• Myelodysplastic syndromes

• Myeloproliferative syndromes b. Match to the patient as follows: a. For Arm A1 (CLOSED):

  • Availability of a 8/8 or 7/8 HLA-matched donor (related or unrelated) defined by Class I (HLA-A, -B, -C) serologic typing (or higher resolution) and Class II (HLA-DRB1) molecular typing.
  • If the donor is a 7/8 HLA-match, the mismatch must be a permissive allelic mismatch as assessed by an independent HLA and transplantation expert. b. For Arm A1 and Arm A3:

  • Availability of a 8/8 HLA-matched donor (related or unrelated) defined by Class I (HLA-A, -B, -C) serologic typing (or higher resolution) and Class II (HLA-DRB1) molecular typing.

    c. For Arm B (CLOSED):

  • Availability of a haploidentical donor who is a ≥ 4/8 but <7/8 match at HLA-A, -B, -C, and -DRB1 (typed using DNA-based high-resolution methods), with at most one mismatch per locus d. For Arm C1 (CLOSED) and C2:

  • Availability of a 8/8 HLA matched donor (related or unrelated) defined by Class I (HLA-A, B, C) serologic typing (or higher resolution) and Class II (HLA DRB1) molecular typing.

    c. Age ≥ 18 and ≤75 years old at the time of enrollment. d. Left ventricular ejection fraction (LVEF) ≥ 45% e. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50% f. Calculated creatinine clearance ≥ 50 mL/min or creatinine < 2.0 mg/dL g. SGPT and SGOT ≤ 3 x ULN, unless elevated secondary to disease Total bilirubin ≤ 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the PI or where hemolysis has been excluded h. Negative serum or urine beta-HCG test in females of childbearing potential within 3 weeks of registration i. Karnofsky performance status ≥ 70%

Donor Inclusion Criteria

1. Age ≥ 18 and ≤ 75 years of age
2. Karnofsky performance status of ≥ 70% defined by institutional standards
3. Seronegative for HIV-1 RNA PCR; HIV 1 and HIV 2 ab (antibody); HTLV-1 and HTLV-2 ab; PCR+ or sAg (surface antigen) hepatitis B ; or PCR or sAg negative for hepatitis C; negative for the Treponema palladum antibody Syphillis screen; and negative for HIV-1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection.
4. In the case that T palladum antibody tests are positive, donors must:

Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history, or Have completed effective antibiotic therapy to treat syphilis, or Have a documented negative non-treponemal test (such as RPR) or in the case of a positive non-treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease e. Match to the patient as follows:

1. Arm A1(CLOSED):

   • Must be a related or unrelated, 8/8 or 7/8-HLA match to recipient at HLAA, -B, -C, and -DRB1. If 7/8 HLA-matched, must be with permissive allelic HLA mismatch as assessed by an independent HLA and transplantation expert.

2. Arm A2 and Arm A3:

   • Must be a related or unrelated, 8/8 HLA match to recipient at HLA A, B, C, and DRB1

3. Arm B (CLOSED):

   • Must be a haploidentical donor who is ≥ 4/8 but < 7/8 match at HLA-A, -B, -C, and -DRB1, with at most one mismatch per locus.

4. Arm C1 (CLOSED) and Arm C2:

   • Must be a related or unrelated 7/8 HLA matched to recipient at HLA A, B, C, DRB1 or -DQB1

f. Must be willing to donate PBSC for up two consecutive days g. Female donors of child-bearing potential must have a negative serum or urine beta HCG test within 3 weeks of mobilization h. Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate i. Agreeable to 2nd donation of PBPC (or bone marrow harvest) in the event of graft failure j. The donor or legal guardian greater than 18 years of age, capable of signing an IRB approved consent form. k. Meets other criteria for donation as specified by standard NMDP guidelines (NMDP donors) or institutional standards (non-NMDP donors) l. Donors not meeting federal eligibility criterion, may nonetheless be included if either apply as follows per 21 CFR § 1271.65:

• The donor is a first-degree or second-degree blood relative of the recipient, or
• Documented urgent medical need (DUMN), meaning no comparable human cell product is available and the recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the Investigator or sub-investigator

Exclusion Criteria:

Recipient Exclusion Criteria

1. Seropositive for any of the following:

   HIV antibodies; hepatitis B surface antigen (sAg); hepatitis C antibodies

2. Patients deemed candidates for fully myeloablative preparative conditioning regimens

d. Candidate for autologous transplant e. Hepatitis B or C with SGPT or SGOT > 3 x ULN f. HIV-positive g. Active uncontrolled bacterial, viral or fungal infection, defined as currently taking antimicrobial therapy and progression of clinical symptoms. h. Uncontrolled CNS disease involvement i. Pregnant or a lactating female j. Positive serum or urine beta-HCG test in females of childbearing potential within 3 weeks of registration k. Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow-up care l. Known allergy or hypersensitivity to, or intolerance of, tacrolimus m. Positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:

• A positive crossmatch of any titer; or
• The presence of anti-donor HLA antibody to any HLA locus n. Any uncontrolled autoimmune disease requiring active immunosuppressive treatment o. Concurrent malignancies or active disease within 1 year, except nonmelanomatous skin cancers that have been curatively resected

Donor Exclusion Criteria

1. Evidence of active infection
2. Seropositive for HIV-1 or-2, HTLV-1 or -2
3. Medical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis
4. Lactating female

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A1: Matched related/matched unrelated donor transplantation (closed); Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:.; Fludarabine (160 mg/m2); Melphalan (50 mg/m2); TBI (4Gy) All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus.	Drug: Fludarabine; Fludarabine (160 mg/m2); Other Names: Beneflur; SH T 586; fludarabine monophosphate; Drug: Tacrolimus; 4-6ng/mL; Other Names: Prograf; Advagraf; fujimycin; Drug: Plerixafor; Dose 0.24 mg/kg, manufactured by Genzyme; Other Names: Mozobil; AMD 3100; LM-3100; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL; Other Names: filgrastim XM02; Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells ("CD34+ HSPC"), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10^6 cells/ kg to 3x10^6 cells/kg; Drug: Melphalan; Melphalan (50 mg/m2); Other Names: Melphalanum
Experimental: Arm B: Haploidentical transplantation (closed); Subjects without an identified matched related or matched unrelated donor will receive a haploidentical transplantation with reduced intensity preparative conditioning: -. Fludarabine (160 mg/m2); Melphalan (100 mg/m2; TBI (4Gy) Patients will receive GVHD prophylaxis with post-transplant cyclophosphamide and tacrolimus.	Drug: Fludarabine; Fludarabine (160 mg/m2); Other Names: Beneflur; SH T 586; fludarabine monophosphate; Device: CliniMACS CD34 Reagent System; The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec; Drug: Tacrolimus; 4-6ng/mL; Other Names: Prograf; Advagraf; fujimycin; Drug: Cyclophosphamide; 40mg/kg; Other Names: alkylating agent; Drug: Plerixafor; Dose 0.24 mg/kg, manufactured by Genzyme; Other Names: Mozobil; AMD 3100; LM-3100; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL; Other Names: filgrastim XM02; Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells ("CD34+ HSPC"), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10^6 cells/ kg to 3x10^6 cells/kg; Drug: Melphalan; Melphalan (50 mg/m2); Other Names: Melphalanum
Experimental: Arm A2: Fully matched (8/8) related/unrelated donor transplantation; Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant: Fludarabine (160 mg/m2); Thiotepa (10 mg/kg); TBI (4Gy) All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus.	Drug: Fludarabine; Fludarabine (160 mg/m2); Other Names: Beneflur; SH T 586; fludarabine monophosphate; Drug: Tacrolimus; 4-6ng/mL; Other Names: Prograf; Advagraf; fujimycin; Drug: Plerixafor; Dose 0.24 mg/kg, manufactured by Genzyme; Other Names: Mozobil; AMD 3100; LM-3100; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL; Other Names: filgrastim XM02; Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells ("CD34+ HSPC"), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10^6 cells/ kg to 3x10^6 cells/kg; Drug: Thiotepa; Thiotepa 10 mg/kg; Other Names: Tepandina
Experimental: Arm A3: Fully (8/8) matched related/unrelated donor transplantation; Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant: Fludarabine (160 mg/m2); Thiotepa (5 mg/kg); TBI (2-3 Gy). All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus.	Drug: Fludarabine; Fludarabine (160 mg/m2); Other Names: Beneflur; SH T 586; fludarabine monophosphate; Drug: Tacrolimus; 4-6ng/mL; Other Names: Prograf; Advagraf; fujimycin; Drug: Plerixafor; Dose 0.24 mg/kg, manufactured by Genzyme; Other Names: Mozobil; AMD 3100; LM-3100; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL; Other Names: filgrastim XM02; Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells ("CD34+ HSPC"), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10^6 cells/ kg to 3x10^6 cells/kg; Drug: Thiotepa; Thiotepa 10 mg/kg; Other Names: Tepandina
Experimental: Arm C1:7/8 mismatched related/unrelated donor transplantation (closed); Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant: Fludarabine (160 mg/m2); Thiotepa (10 mg/kg); TBI (4 Gy) All enrolled subjects will receive GVHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF).	Drug: Fludarabine; Fludarabine (160 mg/m2); Other Names: Beneflur; SH T 586; fludarabine monophosphate; Drug: Tacrolimus; 4-6ng/mL; Other Names: Prograf; Advagraf; fujimycin; Drug: Plerixafor; Dose 0.24 mg/kg, manufactured by Genzyme; Other Names: Mozobil; AMD 3100; LM-3100; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL; Other Names: filgrastim XM02; Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells ("CD34+ HSPC"), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10^6 cells/ kg to 3x10^6 cells/kg; Drug: Thiotepa; Thiotepa 10 mg/kg; Other Names: Tepandina; Drug: Mycophenolate Mofetil (MMF); MMF 1000 mg BID; Other Names: CellCept
Experimental: Arm C2: 7/8 mismatched related/unrelated donor transplantation; Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant: Fludarabine (160 mg/m2); Thiotepa (5 mg/kg); TBI (2-3 Gy) All enrolled subjects will receive GVHD prophylaxis with tacrolimus and ruxolitinib.	Drug: Fludarabine; Fludarabine (160 mg/m2); Other Names: Beneflur; SH T 586; fludarabine monophosphate; Drug: Tacrolimus; 4-6ng/mL; Other Names: Prograf; Advagraf; fujimycin; Drug: Plerixafor; Dose 0.24 mg/kg, manufactured by Genzyme; Other Names: Mozobil; AMD 3100; LM-3100; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL; Other Names: filgrastim XM02; Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells ("CD34+ HSPC"), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10^6 cells/ kg to 3x10^6 cells/kg; Drug: Thiotepa; Thiotepa 10 mg/kg; Other Names: Tepandina; Drug: Ruxolitinib; Ruxolitinib 5 mg BID; Other Names: Jakafi

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determine the GVHD-free relapse-free survival (GRFS) post-HCT ( Arm-A)	Clinical effect will be assessed as graft vs host disease (GVHD)-free relapse free survival (GRFS), GVHD-free is defined as no GVHD symptoms, and relapse free survival is defined as survival at 12 months without relapse. The outcome will be measured in Arm A only.	12 months
Determine the overall survival (OS) post-HCT ( Arm-B)	Overall survival is measured as number of participants alive. Alive at the time of last observation will be censored.	2 years
Incidence of Grade III-IV acute GVHD	Acute GVHD will be staged and graded per Mount Sinai Acute GvHD International Consortium (MAGIC) Standardization criteria.	At baseline, day +30, 60, 90, 180, year 1 and year 2
The incidence and timing of primary graft failure	Primary graft failure is defined as being alive with donor CD3 chimerism <5% at day +30 after transplant without recovery of neutrophils (i.e. without achieving an absolute neutrophil count [ANC] ≥ 500/mm3 for 3 consecutive days) at Day+28	2 years from the Day 0 (day of CD34+ peripheral blood stem cell infusion
Donor CD3 chimerism at Day+60 post-HCT	Defined as a percentage on donor CD3 cells chimerism at day +60 after transplantation.	2 years from the Day 0 (day of CD34+ peripheral blood stem cell infusion)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
GVHD-relapse-free survival	Clinical effect will be assessed as graft vs host disease (GVHD)-free relapse free survival (GRFS), GVHD-free is defined as no GVHD grade 3 and 4, and relapse free survival is defined as survival at 12 months without relapse.	12 months
Overall survival	Overall survival is measured as number of participants alive. Alive at the time of last observation will be censored.	12 months
Secondary graft failure	Secondary graft failure (defined by donor CD3 chimerism <5% at day +30 after transplant) and neutrophil engraftment followed by subsequent decline in ANC < 500/mm3 unresponsive to growth factor therapy, by Day +100	from Day 0 through 100 days
Treatment-emergent adverse events (TEAs)	TEAEs will be categorized by the System Organ Class and preferred term and will be graded according to the CTCAE version 5.0	from Day 0 through 100 days
Acute GVHD (all grades)	Acute GVHD (all grades) will be reported	from Day 0 through 100 days
Steroid-refractory acute GVHD	Steroid refractory acute GVHD will be defined as per the EBMT-NIH-CIBMTR Task Force position statement	within 3-5 days of therapy onset
Non-relapse mortality (NRM)	Non-relapse mortality is measured as number of participants died without relapse/ recurrent disease. Subjects without evidence of relapse/progression at last follow-up date or date of death will be censored.	12 months
Disease-free survival (DFS)	Overall survival is measured as number of participants alive and in remission. Alive in remission at the time of last observation will be censored.	12 months
Chronic GVHD (limited or extensive)	Chronic GVHD will be diagnosed per 2014 International NIH Chronic GVHD Diagnosis and Staging Consensus Working Group criteria (Jagasia 2015). Chronic GVHD scored according to the first day of chronic GVHD onset will be used to calculate cumulative incidence curves. Subjects will be followed for 2 years from the Day 0 (day of CD34+ peripheral blood stem cell infusion) for estimation of cGVHD incidence.	from Day 0 through Year 2

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Neutrophil engraftment	Neutrophil engraftment is defined as having an ANC ≥ 500 cells/µL for three consecutive days. The first of three days will be designated as the day of engraftment.	from Day 0 through 100 days
Time to Platelet engraftment	Platelet engraftment is defined as achieving a platelet count > 20,000 cells/µL for three consecutive days without platelet transfusion in the preceding 7 days. The first of three days will be designated as the day of engraftment.	from Day 0 through 100 days
Incidence of serious infections (grade 2 and greater)	Incidence of serious infections will be measured as event of infections that led to hospitalization or death or required antibiotic treatment. Infections will be graded according to the CTCAE version 5.0	from Day 0 through 100 days

Collaborators and Investigators

• Sponsor: Stanford University
• Collaborators: Orca Biosystems, Inc.
• Investigators: Principal Investigator: Everett Meyer, MD,PhD, Stanford Universiy

Study record dates

Study Major Dates

• Study Start (Actual): September 7, 2021
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: October 11, 2021
• First Submitted That Met QC Criteria: October 12, 2021
• First Posted (Actual): October 21, 2021

Study Record Updates

• Last Update Posted (Actual): February 20, 2024
• Last Update Submitted That Met QC Criteria: February 15, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: GVHD; Reduced intensity conditioning (RIC)
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms by Site; Disease Attributes; Bone Marrow Diseases; Hematologic Diseases; Chronic Disease; Neoplasms; Myelodysplastic Syndromes; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Myeloablative Agonists; Anti-Bacterial Agents; Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antitubercular Agents; Antibiotics, Antitubercular; Calcineurin Inhibitors; Cyclophosphamide; Lenograstim; Melphalan; Fludarabine; Fludarabine phosphate; Tacrolimus; Mycophenolic Acid; Thiotepa; Plerixafor; Alkylating Agents
• Other Study ID Numbers: IRB-60439; BMT372 (Other Identifier: Stanford); NCI-2021-12228 (Other Identifier: NCI Trial ID)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes